Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Pulmonary Tuberculosis Clinical Trial

Official title:

A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01927159
• Other study ID #: IDRI-TBVPX-114
• Status: Completed
• Phase: Phase 1
• First received: August 15, 2013
• Last updated: January 30, 2018
• Start date: September 2013
• Est. completion date: July 2015

Study information

• Verified date: January 2018
• Source: IDRI
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, and immunogenicity in BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Has completed the written informed consent process prior to start of screening evaluations

2. Male or female who is =18 years and =50 years of age at the time of randomization

3. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study

4. Agrees to avoid elective surgery for the full duration of the study

5. For female participants: agrees to avoid pregnancy from 21 days prior to Study Day 0 and for the full duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence(not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide gel

6. Has general good health, confirmed by medical history and physical examination

7. Has body mass index (BMI) between 19 and 33 (weight/height2) by nomogram

8. Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar

Exclusion Criteria:

1. Acute illness at the time of randomization

2. Oral temperature =37.5°C at the time of randomization

3. Clinically significant abnormal laboratory values for any of the following screening laboratory parameters, per local laboratory normal ranges from blood collected within 30 days prior to Study Day 0 randomization as follows:

• hemoglobin, hematocrit, absolute neutrophil count, absolute lymphocyte count, or platelet count below lower limit of normal (LLN)

• white blood cell count above upper limit of normal (ULN) or below LLN (i.e., must be within normal limits)

• ALT, AST, total bilirubin, alkaline phosphatase, creatinine, or blood urea nitrogen (BUN) above ULN

4. Evidence of systemic or local disease process on screening urinalysis

5. Evidence of significant active infection

6. History of treatment for active or latent tuberculosis or evidence of active tuberculosis

7. Shared a residence within the last year prior to randomization with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis

8. History of autoimmune disease or immunosuppression

9. Used immunosuppressive medication within 42 days before randomization (inhaled and topical corticosteroids are permitted)

10. Received immunoglobulin or blood products within 42 days before randomization

11. Received any investigational drug therapy or investigational vaccine within 182 days before randomization, or planned participation in any other investigational study during the study period

12. Received investigational Mtb vaccine at any time prior to randomization

13. Received a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to randomization.

14. Unable to discontinue current chronic prescription drug therapy that can be hepatotoxic or toxic to the bone marrow or kidneys.

15. History or laboratory evidence of immunodeficiency state including but not limited to any laboratory indication of HIV-1 infection

16. History of allergic disease or reactions (including allergy to kanamycin-related antibiotics, allergic reaction to eggs, and severe eczema), likely to be exacerbated by any component of the study vaccine

17. Previous medical history that may compromise the safety of the participant in the study, including but not limited to: severe impairment of pulmonary function from pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease; or uncontrolled epilepsy

18. Evidence of chronic hepatitis (e.g., hepatitis B surface antigen or hepatitis C antibody)

19. Chronic heavy ethanol intake which, in the opinion of the investigator, may compromise the safety of the participant or interfere with the evaluation of the safety of the vaccine

20. Cannabis smoking 3 or more days per week

21. Positive urine test for illicit drugs (opiates, cocaine, amphetamines)

22. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine

23. All female participants: currently pregnant or lactating/nursing; or positive urine pregnancy test during screening or on the day of study injection

24. Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0

25. Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the participant will comply with the protocol or may compromise the safety of the participant

Related Conditions & MeSH terms

• Pulmonary Tuberculosis
• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Biological:
• ID93 + GLA-SE

Other:
• Placebo

Locations

Country	Name	City	State
South Africa	SATVI	Worcester	Western Cape

Sponsors (3)

Lead Sponsor	Collaborator
IDRI	Aeras, South African Tuberculosis Vaccine Initiative

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events	Solicited and unsolicited adverse events will be recorded for 28 days following each study injection; serious adverse events and adverse events of special interest will be recorded for the duration of the study.	294 days
Secondary	Immunogenicity	Immunogenicity will be evaluated by measuring humoral and cellular responses to ID93 + GLA-SE at specified timepoints.	Days 0, 14, 42, 112, 126, 196, 294